[HTML][HTML] Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort …
J Tian, X Yuan, J Xiao, Q Zhong, C Yang, B Liu… - The Lancet …, 2020 - thelancet.com
Background COVID-19 has spread globally. Epidemiological susceptibility to COVID-19 has
been reported in patients with cancer. We aimed to systematically characterise clinical …
been reported in patients with cancer. We aimed to systematically characterise clinical …
[PDF][PDF] Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
…, X Chen, G Dai, J He, J Li, G Li, Y Liu, Z Liu, X Yuan… - Cancer cell, 2022 - cell.com
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
Psychological impact of the coronavirus disease 2019 (COVID-19) outbreak on healthcare workers in China
Y Dai, G Hu, H Xiong, H Qiu, X Yuan - medrxiv, 2020 - medrxiv.org
… Xianglin Yuan and Hong Qiu designed the study. Yuhong Dai, … Xianglin Yuan and Hong
Qiu contributed to the interpretation of … Xianglin Yuan and Hong Qiu are the study guarantors. …
Qiu contributed to the interpretation of … Xianglin Yuan and Hong Qiu are the study guarantors. …
Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous …
…, D Wang, Y Shen, Q Yang, J Zou, RH Xu, X Yuan… - Jama, 2021 - jamanetwork.com
Importance Standard first-line therapy for advanced or metastatic esophageal carcinoma is
chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death …
chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death …
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
…, WT Lim, W Liao, X He, X Chen, Z Liu, X Yuan… - Nature medicine, 2021 - nature.com
Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double-blind…
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double-blind…
M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer
…, F Hu, D Song, Z Hou, W Wu, X Luo, J Wang, X Yuan… - Cancer research, 2019 - AACR
… Xianglin Yuan; Xianglin Yuan … 540-5001540013 to XL Yuan). …
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international …
…, AL Cheng, A Kaseb, A Vogel, M Zhang, L Xu, X Yuan… - The Lancet, 2023 - thelancet.com
Background Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic
tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-…
tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-…
[HTML][HTML] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
…, H Qiu, M Zhang, L Sun, P Peng, Q Yu, X Yuan - Oncotarget, 2017 - ncbi.nlm.nih.gov
Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with
chemotherapy is effective for patients with RAS wild type metastatic colorectal cancer (mCRC)…
chemotherapy is effective for patients with RAS wild type metastatic colorectal cancer (mCRC)…
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
…, Y Chi, Z Li, N Xu, E Li, T Liu, Y Bai, Y Yuan… - The Lancet …, 2020 - thelancet.com
Background Therapeutic options for advanced neuroendocrine tumours (NETs) are limited.
We investigated the efficacy and safety of surufatinib (HMPL-012, sulfatinib) in patients with …
We investigated the efficacy and safety of surufatinib (HMPL-012, sulfatinib) in patients with …
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
…, C Bai, W Wang, J Li, X Yu, Z Li, E Li, X Yuan… - The Lancet …, 2020 - thelancet.com
Background Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumours
(NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the efficacy and …
(NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the efficacy and …
